Open Label Study to Evaluate the Safety Profile and the Quality of Life in Patients Receiving Etanercept for the Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.

Trial Profile

Open Label Study to Evaluate the Safety Profile and the Quality of Life in Patients Receiving Etanercept for the Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Sep 2011

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 23 Sep 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Planned end date changed from 1 Sep 2011 to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Planned number of patients changed from 1000 to 909 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top